The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib

Abstract

Pharmacometric methods have hugely benefited from progress in analytical and computer sciences during the past decades, and play nowadays a central role in the clinical development of new medicinal drugs. It is time that these methods translate into patient care through therapeutic drug monitoring (TDM), due to become a mainstay of precision medicine no less than genomic approaches to control variability in drug response and improve the efficacy and safety of treatments. In this review, we make the case for structuring TDM development along five generic questions: 1) Is the concerned drug a candidate to TDM? 2) What is the normal range for the drug's concentration? 3) What is the therapeutic target for the drug's concentration? 4) How to adjust the dosage of the drug to drive concentrations close to target? 5) Does evidence support the usefulness of TDM for this drug? We exemplify this approach through an overview of our development of the TDM of imatinib, the very first targeted anticancer agent. We express our position that a similar story shall apply to other drugs in this class, as well as to a wide range of treatments critical for the control of various life-threatening conditions. Despite hurdles that still jeopardize progress in TDM, there is no doubt that upcoming technological advances will shape and foster many innovative therapeutic monitoring methods.

Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology

“…Imatinib now has routine TDM as part of practice. As such it is a paradigmatic example of how and why TDM should be performed 14 …”

Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management

“…It is also worth noting that the use of the Internet for drug alerts and drug monitoring should become the mainstream for adherence improvement in the near future. [123][124][125] The last but not least, drug therapy alone is sometimes difficult to achieve satisfactory curative effects, thus the combination of non-drug therapy, such as functional training, should be a beneficial supplement for the treatment of COPD.…”

The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases

“…The sampling is mostly performed at trough (i.e., immediately before the next dose), since the trough serum concentration well reflects the overall exposure to the drug and systemic drug clearance, although monitoring at other time-points may be possible, as well. The serum concentration is subsequently compared to the established optimal drug concentration, at which the patient is most likely to respond, based on the known exposure-response relationship [ 21 ]. The optimal concentration is specific for each mAb, disease indication, dosing regimen and treatment time-point.…”